Cypress Asset Management Inc Regeneron Pharmaceuticals, Inc. Transaction History

Cypress Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$274.13 - $376.51 $452,314 - $621,241	-1,650 Closed	0 $0
Q3 2019 Oct 21, 2019	SELL	$273.46 - $318.39 $57,426 - $66,861	-210 Reduced 11.29%	1,650 $458,000
Q2 2019 Aug 13, 2019	SELL	$299.6 - $414.82 $1,498 - $2,074	-5 Reduced 0.27%	1,860 $582,000
Q1 2019 Apr 29, 2019	SELL	$372.08 - $439.57 $40,184 - $47,473	-108 Reduced 5.47%	1,865 $766,000
Q4 2018 Feb 12, 2019	SELL	$335.82 - $403.04 $193,096 - $231,748	-575 Reduced 22.57%	1,973 $737,000
Q3 2018 Oct 19, 2018	SELL	$351.14 - $408.51 $125,356 - $145,838	-357 Reduced 12.29%	2,548 $1.03 Million
Q2 2018 Jul 27, 2018	SELL	$284.6 - $344.99 $123,801 - $150,070	-435 Reduced 13.02%	2,905 $1 Million
Q1 2018 May 14, 2018	SELL	$315.82 - $393.78 $1.2 Million - $1.49 Million	-3,791 Reduced 53.16%	3,340 $1.15 Million
Q4 2017 Jan 31, 2018	SELL	$358.63 - $469.95 $518,578 - $679,547	-1,446 Reduced 16.86%	7,131 $2.68 Million
Q3 2017 Nov 08, 2017	BUY	$431.38 - $504.0 $3.7 Million - $4.32 Million	8,577	8,577 $3.84 Million

1,532

84.1M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $80.3B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Cypress Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cypress Asset Management Inc with notifications on news.